BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 35191283)

  • 21. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.
    Maniaci C; Hughes SJ; Testa A; Chen W; Lamont DJ; Rocha S; Alessi DR; Romeo R; Ciulli A
    Nat Commun; 2017 Oct; 8(1):830. PubMed ID: 29018234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design Principles Involving Protein Disorder Facilitate Specific Substrate Selection and Degradation by the Ubiquitin-Proteasome System.
    Guharoy M; Bhowmick P; Tompa P
    J Biol Chem; 2016 Mar; 291(13):6723-31. PubMed ID: 26851277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure driven compound optimization in targeted protein degradation.
    Leissing TM; Luh LM; Cromm PM
    Drug Discov Today Technol; 2020 Dec; 37():73-82. PubMed ID: 34895657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and Evaluation of Cereblon-Recruiting HaloPROTACs.
    Ody BK; Zhang J; Nelson SE; Xie Y; Liu R; Dodd CJ; Jacobs SE; Whitzel SL; Williams LA; Gozem S; Turlington M; Yin J
    Chembiochem; 2023 Nov; 24(21):e202300498. PubMed ID: 37625128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploiting ELIOT for Scaffold-Repurposing Opportunities: TRIM33 a Possible Novel E3 Ligase to Expand the Toolbox for PROTAC Design.
    Palomba T; Tassone G; Vacca C; Bartalucci M; Valeri A; Pozzi C; Cross S; Siragusa L; Desantis J
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perspectives on the development of first-in-class protein degraders.
    Rambacher KM; Calabrese MF; Yamaguchi M
    Future Med Chem; 2021 Jul; 13(14):1203-1226. PubMed ID: 34015962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted Protein Degradation through E2 Recruitment.
    Forte N; Dovala D; Hesse MJ; McKenna JM; Tallarico JA; Schirle M; Nomura DK
    ACS Chem Biol; 2023 Apr; 18(4):897-904. PubMed ID: 36940189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemically Induced Cellular Proteolysis: An Emerging Therapeutic Strategy for Undruggable Targets.
    Moon S; Lee BH
    Mol Cells; 2018 Nov; 41(11):933-942. PubMed ID: 30486612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Modular Chemistry Platform for the Development of a Cereblon E3 Ligase-Based Partial PROTAC Library.
    Almodóvar-Rivera CM; Zhang Z; Li J; Xie H; Zhao Y; Guo L; Mannhardt MG; Tang W
    Chembiochem; 2023 Oct; 24(20):e202300482. PubMed ID: 37418320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of E3 Ligase Ligands for Target Protein Degradation.
    Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteasome substrate receptors and their therapeutic potential.
    Osei-Amponsa V; Walters KJ
    Trends Biochem Sci; 2022 Nov; 47(11):950-964. PubMed ID: 35817651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expanding PROTACtable genome universe of E3 ligases.
    Liu Y; Yang J; Wang T; Luo M; Chen Y; Chen C; Ronai Z; Zhou Y; Ruppin E; Han L
    Nat Commun; 2023 Oct; 14(1):6509. PubMed ID: 37845222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities.
    Kastl JM; Davies G; Godsman E; Holdgate GA
    SLAS Discov; 2021 Apr; 26(4):524-533. PubMed ID: 33632029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A label-free quantitative proteomics strategy to identify E3 ubiquitin ligase substrates targeted to proteasome degradation.
    Burande CF; Heuzé ML; Lamsoul I; Monsarrat B; Uttenweiler-Joseph S; Lutz PG
    Mol Cell Proteomics; 2009 Jul; 8(7):1719-27. PubMed ID: 19376791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic approaches to identify E3 ligase substrates.
    Iconomou M; Saunders DN
    Biochem J; 2016 Nov; 473(22):4083-4101. PubMed ID: 27834739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
    Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
    Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway.
    Collins I; Wang H; Caldwell JJ; Chopra R
    Biochem J; 2017 Mar; 474(7):1127-1147. PubMed ID: 28298557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Advances in the preclinical and clinical research of proteolysis targeting chimera].
    Liu Z; Liu S
    Sheng Wu Gong Cheng Xue Bao; 2023 Sep; 39(9):3615-3627. PubMed ID: 37805842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HECT ubiquitin ligases as accessory proteins of the plant proteasome.
    Wang Z; Spoel SH
    Essays Biochem; 2022 Aug; 66(2):135-145. PubMed ID: 35635104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of the ubiquitin proteasome system in hematologic malignancies.
    Sahasrabuddhe AA; Elenitoba-Johnson KS
    Immunol Rev; 2015 Jan; 263(1):224-39. PubMed ID: 25510280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.